Autopsy report · NCT00609622
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
Cause of deathNo reason given
“See termination reason in detailed description.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 3 years 3 months before it stopped.
- 191 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Colorectal Neoplasms
- Interventions
- sunitinib; mFOLFOX6; bevacizumab; mFOLFOX6
- Participants
- 191
- Sites
- 97
- Countries
- Denmark, Germany, Japan, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.